再生元制药公司 REGN 深 沪
等待开盘 12-03 09:30:00 美东时间
741.58
-8.530
-1.14%
华盛通- 最 高747.00
- 今 开742.12
- 成交量 59.16万股
- 最 低 731.00
- 昨 收 750.11
- 总市值 800.91亿
- 52周最高 790.98
- 市盈率 静 19.34
- 换手率 0.55%
- 52周最低 474.7269
- 委 比 -98.47%
- 总股本 1.08亿
- 历史最高 1207.6799
- 量 比 0.71
- 振 幅 2.13%
- 历史最低 39.31
- 每 手 1
- 风险率 74.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power
Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tumor response, supporting plans for Japan registration.
今天 00:56
Regeneron inks deal with Tessera to develop gene editing therapy
Regeneron Pharmaceuticals (REGN) will pay privately held Tessera Therapeutics an upfront payment and make an equity investment totaling $150M to work on development of TSRA-196, the latter's in vivo g...
12-02 04:29
2026创新药，大干一场
（来源：商图药讯） 个人努力，在时代Beta面前无足轻重？ 总有老登否定你的个人努力，将功劳归之于时代红利，但是，没有错过时代红利，本身也是一种能力。 创...
12-01 19:30
Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe
Sanofi faces a surprise tax probe in France as Dupixent secures EU approval for treating chronic spontaneous urticaria.
11-26 02:30
汇丰：首予再生元制药(REGN.US)“买入”评级 看好Eylea HD放量及肿瘤管线多点催化
汇丰银行发表研报，首次覆盖再生元制药，并给予 “买入” 评级，目标价为890美元。
11-25 15:32
CytomX Therapeutics to Present at Upcoming December Investor Conferences
CytomX Therapeutics announced that its management will participate in two investor conferences in December 2025: the 8th Annual Evercore Healthcare Conference on December 2 in Coral Gables, FL, and the Piper Sandler 37th Annual Healthcare Conference on December 4 in New York, NY. Both events will feature fireside chats and live webcasts available on CytomX’s website. The company, focused on developing conditionally activated biologics for oncolog...
11-25 13:00
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Dupixent has been approved in the EU for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 and older who have an inadequate response to antihistamines. The approval is based on Phase 3 trials showing significant reduction in itch and hives compared to placebo. Dupixent, which inhibits IL-4 and IL-13, is now approved for seven chronic inflammatory diseases in the EU. Approximately 270,000 adu...
11-25 06:00
'No One's Buying Homes Here': Cramer Warns On This Housing Stock
Cramer prefers Netflix (NFLX) over FuboTV (FUBO). Rocket Companies (RKT) and Regeneron Pharmaceuticals (REGN) also discussed. FDA approves new drug for Regeneron.
11-22 02:51
